Congenital myasthenic syndromes: Achievements and limitations of phenotype‐guided gene‐after‐gene sequencing in diagnostic practice: A study of 680 patients

Congenital myasthenic syndromes (CMSs) are clinically and genetically heterogeneous disorders characterized by a neuromuscular transmission defect. Even though CMSs are genetic disorders, they are highly treatable, and the appropriate drug treatment depends on the underlying genetic defect. This highlights the importance of genetic testing in CMS. In recent years, the molecular basis of CMS has constantly broadened and disease‐associated mutations have been identified in 14 genes encoding proteins of the neuromuscular junction. In the dawn of novel sequencing strategies, we report on our 14‐year experience in traditional Sanger‐based mutation screening of a large cohort of 680 independent patients with suspected CMS. In total, we identified disease‐causing mutations in 299 patients (44%) of patients in various known CMS genes, confirming the high degree of genetic heterogeneity associated with the disease. Apart from four known founder mutations, and a few additional recurrent mutations, the majority of variants are private, found in single families. The impact of previously reported genotype–phenotype correlations on efficiency of genetic testing was analyzed in our population. Taking our experiment into account, we present our algorithm for genetic testing in CMS. Hum Mutat 33:1474–1484, 2012. © 2012 Wiley Periodicals, Inc.

[1]  Jacqueline Palace,et al.  Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations , 2012, Journal of Neurology.

[2]  H. Lochmüller,et al.  A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome , 2012, Journal of Neurology.

[3]  A. Engel.  Congenital Myasthenic Syndromes in 2012 , 2012, Current Neurology and Neuroscience Reports.

[4]  M. Milone,et al.  Endplate structure and parameters of neuromuscular transmission in sporadic centronuclear myopathy associated with myasthenia , 2011, Neuromuscular Disorders.

[5]  N. Gilhus,et al.  Investigation for RAPSN and DOK‐7 mutations in a cohort of seronegative myasthenia gravis patients , 2011, Muscle & nerve.

[6]  T. Strom,et al.  Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. , 2011, American journal of human genetics.

[7]  F. Muntoni,et al.  Congenital fibre type disproportion associated with mutations in the tropomyosin 3 (TPM3) gene mimicking congenital myasthenia , 2010, Neuromuscular Disorders.

[8]  B. Eymard,et al.  Multiexon deletions account for 15% of congenital myasthenic syndromes with RAPSN mutations after negative DNA sequencing , 2010, Journal of Medical Genetics.

[9]  B. Brais,et al.  DOK7 mutations presenting as a proximal myopathy in French Canadians , 2010, Neuromuscular Disorders.

[10]  H. Christen,et al.  Long-term follow-up in patients with congenital myasthenic syndrome due to CHAT mutations. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[11]  Hanns Lochmüller,et al.  Molecular characterisation of congenital myasthenic syndromes in Southern Brazil , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  F. Muntoni,et al.  Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies , 2009, Neuromuscular Disorders.

[13]  E. Génin,et al.  The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa , 2008, Neurology.

[14]  F. Muntoni,et al.  Congenital Myasthenic Syndromes in childhood: Diagnostic and management challenges , 2008, Journal of Neuroimmunology.

[15]  Jacqueline Palace,et al.  Congenital Myasthenic Syndromes and the Formation of the Neuromuscular Junction , 2008, Annals of the New York Academy of Sciences.

[16]  E. Bertini,et al.  Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. , 2008, Brain : a journal of neurology.

[17]  Hanns Lochmüller,et al.  Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission , 2007, Expert Reviews in Molecular Medicine.

[18]  Hanns Lochmüller,et al.  Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. , 2007, Brain : a journal of neurology.

[19]  F. Schreiner,et al.  Novel COLQ mutation 950delC in synaptic congenital myasthenic syndrome and symptomatic heterozygous relatives , 2007, Neuromuscular Disorders.

[20]  Hanns Lochmüller,et al.  Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine , 2006, Neuromuscular Disorders.

[21]  M. Vorgerd,et al.  Facing the genetic heterogeneity in neuromuscular disorders: Linkage analysis as an economic diagnostic approach towards the molecular diagnosis , 2006, Neuromuscular Disorders.

[22]  Hanns Lochmüller,et al.  126th International Workshop: Congenital Myasthenic Syndromes, 24–26 September 2004, Naarden, The Netherlands , 2005, Neuromuscular Disorders.

[23]  Hanns Lochmüller,et al.  The congenital myasthenic syndrome mutation RAPSN N88K derives from an ancient Indo-European founder , 2004, Journal of Medical Genetics.

[24]  Hanns Lochmüller,et al.  Synaptic congenital myasthenic syndrome in three patients due to a novel missense mutation (T441A) of the COLQ gene. , 2004, Neuropediatrics.

[25]  Hanns Lochmüller,et al.  Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in European patients , 2003, Neurology.

[26]  A. Barois,et al.  Possible founder effect of rapsyn N88K mutation and identification of novel rapsyn mutations in congenital myasthenic syndromes , 2003, Journal of medical genetics.

[27]  K. Ohno,et al.  E-box mutations in the RAPSN promoter region in eight cases with congenital myasthenic syndrome. , 2003, Human molecular genetics.

[28]  Hanns Lochmüller,et al.  Congenital myasthenic syndrome due to a novel missense mutation in the gene encoding choline acetyltransferase , 2003, Neuromuscular Disorders.

[29]  A. Briguet,et al.  A newly identified chromosomal microdeletion and an N-box mutation of the AChR epsilon gene cause a congenital myasthenic syndrome. , 2002, Brain : a journal of neurology.

[30]  H. Lochmüller,et al.  A common mutation (ε1267delG) in congenital myasthenic patients of Gypsy ethnic origin , 1999 .

[31]  K. Ohno,et al.  Congenital myasthenic syndrome caused by a mutation in the Ets-binding site of the promoter region of the acetylcholine receptor ϵ subunit gene , 1999, Neuromuscular Disorders.

[32]  M. Hutchinson,et al.  Mutation of the acetylcholine receptor ε‐subunit promoter in congenital myasthenic syndrome , 1999 .

[33]  J. Palace,et al.  The congenital myasthenic syndromes , 2008, Journal of Neuroimmunology.

[34]  K. Ohno,et al.  New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. , 1996, Human molecular genetics.

[35]  J. Huisman.  The Netherlands , 1996, The Lancet.

[36]  K. Ohno,et al.  Mutation of the acetylcholine receptor α subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity , 1995, Neuron.

[37]  P. Špalek.  [Congenital myasthenic syndrome]. , 1991, Ceskoslovenska neurologie a neurochirurgie.

[38]  A. Engel.  Congenital Myasthenic Syndromes , 1985, Journal of child neurology.

[39]  S. Sine,et al.  What Have We Learned from the Congenital Myasthenic Syndromes , 2009, Journal of Molecular Neuroscience.

[40]  Hanns Lochmüller,et al.  Clinical variability of CMS-EA (congenital myasthenic syndrome with episodic apnea) due to identical CHAT mutations in two infants. , 2005, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[41]  Hanns Lochmüller,et al.  A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. , 1999, Neurology.

[42]  M. Hutchinson,et al.  Mutation of the acetylcholine receptor epsilon-subunit promoter in congenital myasthenic syndrome. , 1999, Annals of neurology.